New Treatments & Clinical Trials for Ewing Sarcoma

Ewing sarcoma is a rare bone and soft tissue cancer that most often affects children and young adults. Treatment typically involves chemotherapy, surgery or radiation, and more chemotherapy. About 70% of people with localized disease survive five years, but outcomes for metastatic or relapsed disease remain poor despite decades of using the same chemotherapy drugs.

What's actually going on in research

Trials are testing targeted therapies against the EWSR1 fusion protein that drives these tumors, immunotherapies including CAR T-cells and checkpoint inhibitors, and new chemotherapy combinations. Researchers are also studying whether adding drugs that block insulin-like growth factor or other growth signals can improve outcomes, particularly for disease that returns after initial treatment.

What to know before you search

Eligibility typically depends on whether the disease is newly diagnosed or relapsed, extent of spread, prior treatments received, and age.

What types of trials are currently open

• Frontline treatment trials — Testing whether adding targeted drugs or immunotherapy to standard chemotherapy improves survival for newly diagnosed Ewing sarcoma.
• Relapsed disease trials — Studies of new drug combinations or novel agents for Ewing sarcoma that has returned after initial treatment, where options are extremely limited.
• Immunotherapy trials — Testing CAR T-cells, checkpoint inhibitors, or cancer vaccines to activate the immune system against Ewing tumors.
• Targeted therapy trials — Studies of drugs designed to block specific proteins or pathways that Ewing sarcoma cells depend on to grow.
• Biology studies — Research collecting tumor samples and tracking disease over time to understand what makes some Ewing tumors resistant to treatment.